Sitafloxacin
Sitafloxacin structure
|
Common Name | Sitafloxacin | ||
|---|---|---|---|---|
| CAS Number | 127254-12-0 | Molecular Weight | 409.814 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 629.2±55.0 °C at 760 mmHg | |
| Molecular Formula | C19H18ClF2N3O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 334.3±31.5 °C | |
Use of SitafloxacinSitafloxacin is a new-generation, broad-spectrum oral fluoroquinolone antibiotic.Target: AntibacterialSitafloxacin, a new-generation, broad-spectrum oral fluoroquinolone that is very active against many Gram-positive, Gram-negative and anaerobic clinical isolates, including strains resistant to other fluoroquinolones, was recently approved in Japan for the treatment of respiratory and urinary tract infections [1]. In terms of clinical efficacy, oral sitafloxacin was noninferior to oral levofloxacin in the treatment of community-acquired pneumonia or an infectious exacerbation of chronic respiratory tract disease, noninferior to oral tosufloxacin in the treatment of community-acquired pneumonia, and noninferior to oral levofloxacin in the treatment of complicated urinary tract infections, according to the results of randomized, double-blind, multicentre, noninferiority trials. Noncomparative studies demonstrated the efficacy of oral sitafloxacin in otorhinolaryngological infections, urethritis in men, C. trachomatis-associated cervicitis in women and odontogenic infections [2]. |
| Name | 7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(2S)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Sitafloxacin is a new-generation, broad-spectrum oral fluoroquinolone antibiotic.Target: AntibacterialSitafloxacin, a new-generation, broad-spectrum oral fluoroquinolone that is very active against many Gram-positive, Gram-negative and anaerobic clinical isolates, including strains resistant to other fluoroquinolones, was recently approved in Japan for the treatment of respiratory and urinary tract infections [1]. In terms of clinical efficacy, oral sitafloxacin was noninferior to oral levofloxacin in the treatment of community-acquired pneumonia or an infectious exacerbation of chronic respiratory tract disease, noninferior to oral tosufloxacin in the treatment of community-acquired pneumonia, and noninferior to oral levofloxacin in the treatment of complicated urinary tract infections, according to the results of randomized, double-blind, multicentre, noninferiority trials. Noncomparative studies demonstrated the efficacy of oral sitafloxacin in otorhinolaryngological infections, urethritis in men, C. trachomatis-associated cervicitis in women and odontogenic infections [2]. |
|---|---|
| Related Catalog | |
| References |
[2]. Keating, G.M., Sitafloxacin: in bacterial infections. Drugs, 2011. 71(6): p. 731-44. |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 629.2±55.0 °C at 760 mmHg |
| Molecular Formula | C19H18ClF2N3O3 |
| Molecular Weight | 409.814 |
| Flash Point | 334.3±31.5 °C |
| Exact Mass | 409.100464 |
| PSA | 88.56000 |
| LogP | 0.87 |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.699 |
| Storage condition | 2-8°C |
|
~%
Sitafloxacin CAS#:127254-12-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 37, # 20 p. 3344 - 3352 |
|
~%
Sitafloxacin CAS#:127254-12-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 37, # 20 p. 3344 - 3352 |
|
~%
Sitafloxacin CAS#:127254-12-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 37, # 20 p. 3344 - 3352 |
|
~%
Sitafloxacin CAS#:127254-12-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 37, # 20 p. 3344 - 3352 |
|
~%
Sitafloxacin CAS#:127254-12-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 37, # 20 p. 3344 - 3352 |
|
~%
Sitafloxacin CAS#:127254-12-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 37, # 20 p. 3344 - 3352 |
![7-(S)-amino-5-[1(R)-phenylethyl]-5-azaspiro[2.4]heptane structure](https://image.chemsrc.com/caspic/287/127199-41-1.png)
![7-(S)-amino-5-[1(R)-phenylethyl]-4-oxo-5-azaspiro[2.4]heptane structure](https://image.chemsrc.com/caspic/228/127199-38-6.png)
![(S)-tert-Butyl 5-azaspiro[2.4]heptan-7-ylcarbamate structure](https://image.chemsrc.com/caspic/135/127199-45-5.png)
| DU-6859a |
| MFCD00903720 |
| DU 6859a |
| 7-((7S)-7-Amino-5-azaspiro[2.4]hept-5-yl)-8-chloro-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid |
| 7-[(7S)-7-Amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid |
| 7-[(7S)-7-Amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| (1R-(1a(S*),2a))-7-(7-Amino-5-azaspiro[2.4]hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid |
| Gracevit |
| 3-Quinolinecarboxylic acid, 7-[(7S)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo- |
| Sitafloxacin |